* Cost savings opportunity compared to: Semaglutide 2.5mg/ml concentration * This vial size will last twice as long as the 2.5mg/ml-4ml vial, a $40 savings compared to purchasing #2 vials of the lower concentration
Avoid in Fluid Replacement: Not intended for IV fluid replacement or as a standalone injection
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (familiar brand names include Jardiance, Farxiga, Ozempic, Wegovy, Mounjaro, Zepbound, Victoza ) are increasingly popular options, not only for glycemic control among patients with diabetes, but also for heart failure management and weight losseven in non-diabetics
Diabetes Care 48(1):S207-38 Marx N, Federici M, Schtt K, Mller-Wieland D, Ajjan RA, Antunes MJ et al (2023) 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)
